FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

The FDA on Wednes­day ap­proved the first gene ther­a­py for a chron­ic con­di­tion — blue­bird bio’s new Zyn­te­glo (beti-cel) as a po­ten­tial­ly cu­ra­tive treat­ment for those …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER